-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Sihua Pharmaceutical Group’s Mecobalamin Injection Has Been Approved for Consistency Evaluation.
Category:
Time：2022-09-13
Recently, the methylcobalamin injection (1 ml: 0.5 mg) developed by Shijiazhuang Fourth Pharmaceutical Group has been approved by the National Medical Products Administration and has passed the evaluation of consistency in quality and efficacy for generic drugs.
Recently, the methylcobalamin injection (1 ml: 0.5 mg) developed by Shijiazhuang No.4 Pharmaceutical Group has been approved by the National Medical Products Administration and has passed the evaluation of consistency in quality and efficacy for generic drugs.
It is reported that methylcobalamin injection is primarily used to treat peripheral neuropathy and megaloblastic anemia caused by vitamin B12 deficiency.
Over the past two years, Shijiazhuang No.4 Pharmaceutical has been steadily advancing and intensifying its efforts in the development of innovative drugs, generic drugs, and active pharmaceutical ingredients, as well as in consistency evaluation studies, yielding abundant and well-accumulated innovative results. As of now, Shijiazhuang No.4 Pharmaceutical Group has had a total of 28 drug varieties comprising 37 specifications either approved or deemed to have passed the national consistency evaluation for generic drug quality and efficacy, placing it at the forefront of the industry in terms of both the number of approvals and the pace of progress.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license